Key Takeaways
- HIMS shares jumped 7% in premarket trading Thursday, building on Wednesday’s 10% advance for a fourth consecutive session of gains
- The telehealth company’s stock has climbed 64% during the current week — marking its strongest weekly showing ever
- A groundbreaking partnership with Novo Nordisk enables HIMS to distribute FDA-approved weight-loss medications Ozempic and Wegovy through its platform
- Multiple analyst upgrades followed: Barclays increased its target to $29 from $25 maintaining “overweight”; Bank of America upgraded to “neutral” from “underperform” with a $23 target
- Fourth-quarter earnings per share of $0.08 significantly exceeded analyst expectations of $0.02, while revenue of $617.8M fell marginally short of the $619.5M forecast
Hims & Hers Health (HIMS) is experiencing an extraordinary week. The digital health company’s shares rose approximately 7% during Thursday’s premarket session, extending Wednesday’s 10% rally. This marks the fourth consecutive trading day of positive momentum.
Hims & Hers Health, Inc., HIMS
As of Wednesday’s closing bell, HIMS had rocketed 64% higher for the week. This represents the company’s strongest weekly performance since going public.
The explosive rally kicked off Monday following the announcement that Novo Nordisk would distribute its blockbuster weight-loss medications via the Hims & Hers digital platform. The partnership resolves a significant legal uncertainty that had been weighing on investor sentiment.
The arrangement allows Hims & Hers to offer FDA-approved GLP-1 medications Ozempic and Wegovy directly to consumers through its telehealth service. Wall Street analysts have identified this as a significant catalyst for both revenue growth and margin expansion.
Midday Wednesday saw HIMS trading at $26.17, representing a $2.70 daily increase, accompanied by trading volume of 51.6 million shares — substantially exceeding the typical 33.3 million average.
Wall Street Upgrades Follow Partnership News
The Novo Nordisk collaboration sparked multiple analyst revisions. Barclays elevated its price objective to $29 from $25 while reaffirming an “overweight” recommendation. This target suggests roughly 10.8% potential upside from present levels.
Bank of America shifted its rating to “neutral” from “underperform” and substantially raised its target to $23 from $12.50. Deutsche Bank also increased its projection to $28 from $25, maintaining a “hold” stance.
According to MarketBeat data, the consensus rating stands at “Hold” with an average price target of $30.75. The breakdown includes three Buy ratings, thirteen Hold recommendations, and one Sell rating.
Options activity also reached unusually elevated levels, with approximately 322,000 call contracts changing hands — suggesting significant bullish sentiment that could accelerate upward price movement.
Strong Q4 Results and Capital Allocation
HIMS unveiled its fourth-quarter financial results on February 23. Earnings per share of $0.08 substantially surpassed the $0.02 analyst consensus. Revenue totaled $617.8 million, slightly below the anticipated $619.5 million.
Despite the minor revenue miss, sales increased 28.4% compared to the prior-year period. The company delivered a return on equity of 22.48% alongside a net profit margin of 5.47%.
The board simultaneously authorized a $250 million share repurchase program, representing approximately 3% of outstanding shares. Such authorizations generally indicate management’s confidence that shares are trading below intrinsic value.
For the full fiscal year ahead, Wall Street projects EPS of $0.29.
The stock’s 52-week trading range spans $13.74 to $70.43. At Wednesday’s close, shares traded comfortably above the 50-day moving average of $24.31 but remained below the 200-day moving average of $37.75.
Notwithstanding this week’s substantial gains, elevated short interest remains a factor to monitor. Analysts have noted that squeeze dynamics could introduce volatility — rapid gains fueled by short covering can reverse abruptly once speculative momentum dissipates.
Institutional investors collectively control 63.52% of HIMS shares. Company insiders own 17.71%, though insider selling totaled 80,463 shares during the most recent quarter.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
